导航

| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.13% | 2098/4773 |
| 近一周 | -1.74% | 1551/5458 |
| 近一月 | -6.91% | 3819/5421 |
| 近一季 | 14.54% | 104/5205 |
| 近半年 | 6.06% | 730/4920 |
| 近一年 | -15.09% | 3716/4361 |
| 近两年 | 27.06% | 2447/2954 |
| 近三年 | -5.32% | 2006/2253 |
| 成立以来 | -4.90% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.86% 3441/4961 |
-0.37% 3290/5312 |
- - |
- - |
| 2025 | 9.67% 2857/4813 |
3.89% 1024/3635 |
2.27% 1701/4076 |
23.58% 1531/4524 |
-16.47% 4387/4813 |
| 2024 | -20.39% 2528/3463 |
-15.41% 2543/2808 |
-11.90% 2572/3014 |
18.35% 1021/3129 |
-9.74% 2948/3463 |
| 2023 | -5.67% 761/2656 |
-0.25% 1787/2280 |
-8.47% 2000/2385 |
0.92% 331/2515 |
2.38% 65/2655 |
| 2022 | -24.85% 1265/2207 |
-12.81% 658/1919 |
-3.83% 1840/2016 |
-18.23% 1690/2113 |
9.59% 205/2208 |
| 2021 | -15.99% 1163/1822 |
-4.75% 884/1255 |
9.69% 530/1330 |
-12.86% 1320/1466 |
-7.72% 1572/1822 |
| 2020 | 60.44% 123/1250 |
14.43% 5/1028 |
41.02% 5/1067 |
3.63% 973/1164 |
-4.06% 1136/1184 |
| 2019 | - - |
- - |
- - |
13.57% 22/850 |
5.26% 733/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 国泰中证生物医药ETF VS. 长安沪深300非周期A(740101) |